So, the search continues." Perhaps, we need to be far more...

So, the search continues.

" Perhaps, we need to be far more selective and enroll genetically selected patients who are likely to have greater tumor mutational burden, or mismatch-repair, which is being explored in an ongoing study led by the Alliance consortium (NCT04145115). We are just scratching the surface here, as multiple such ideas are currently under testing, with the hope that one of these days we will find another drug with survival benefit in glioblastoma, the first since temozolomide was approved almost two decades ago. "

Good GBM AGILE data could light a fire?